Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

Next Previous
Trial Profile

A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buntanetap (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Annovis Bio

Most Recent Events

  • 12 Nov 2025 According to an Annovis Bio media release, the first patients have successfully completed the 6-month treatment period, demonstrating continued progress toward trial completion.
  • 06 Nov 2025 According to an Annovis Bio media release, all 84 sites in this trial in early AD are now fully activated and enrolling participants,and Company on track to deliver symptomatic data in the second half of 2026.
  • 12 Aug 2025 According to an Annovis Bio media release, 76 U.S. sites secured and 46 currently enrolling patients. The remaining sites are expected to begin enrollment shortly. This pivotal Phase 3 trial has attracted strong participation, with 38 patients already receiving buntanetap or placebo and nearly 200 more in screening a number that continues to grow each day with screen failure rate being as expected at 50%.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top